Cargando…
Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage resp...
Autores principales: | Kinget, Lisa, Bechter, Oliver, Punie, Kevin, Debruyne, Philip R., Brems, Hilde, Clement, Paul, Roussel, Eduard, Van Herck, Yannick, Albersen, Maarten, Baldewijns, Marcella, Schöffski, Patrick, Beuselinck, Benoit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395488/ https://www.ncbi.nlm.nih.gov/pubmed/34449592 http://dx.doi.org/10.3390/curroncol28050280 |
Ejemplares similares
-
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series
por: Sukumar, Jasmine, et al.
Publicado: (2021) -
CHEK2 contribution to hereditary breast cancer in non-BRCA families
por: Desrichard, Alexis, et al.
Publicado: (2011) -
Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014) -
In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2
por: Kim, S, et al.
Publicado: (2008) -
Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)